SARA Abed

Ms. SARA Abed


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018
Verified
Book Chapter
Closed access
BCBalakumar Chandrasekaran
Balakumar Chandrasekaran
SASARA Abed
SARA Abed
OAOmar Al-Attraqchi
Omar Al-Attraqchi
KKKaushik Kuche
Kaushik Kuche
RTRakesh K. Tekade
Rakesh K. Tekade

3 October 2019 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDPran Kishore Deb
Pran Kishore Deb
SDSatyendra Deka
Satyendra Deka
PBPobitra Borah
Pobitra Borah
SASARA Abed
SARA Abed
KKKarl-Norbert Klotz
Karl-Norbert Klotz
Adenosine is a purine nucleoside, responsible for the regulation of a wide range of physiological and pathophysiological conditions by binding with four G-protein-coupled receptors (GPCRs), namely A1, A2A, A2B and A3 adenosine receptors (ARs). In particular, A1 AR is ubiquitously present, mediating a variety of physiological processes throughout the body, thus represents a promising drug target for the management of various pathological conditions. Agonists of A1 AR are found to be useful for the treatment of atrial arrhythmia, angina, type-2 diabetes, glaucoma, neuropathic pain, epilepsy, depression and Huntington’s disease, whereas antagonists are being investigated for the treatment of diuresis, congestive heart failure, asthma, COPD, anxiety and dementia. However, treatment with full A1 AR agonists has been associated with numerous challenges like cardiovascular side effects, off-target activation as well as desensitization of A1 AR leading to tachyphylaxis. In this regard, partial agonists of A1 AR have been found to be beneficial in enhancing insulin sensitivity and subsequently reducing blood glucose level, while avoiding severe CVS side effects and tachyphylaxis. Allosteric enhancer of A1 AR is found to be potent for the treatment of neuropathic pain, culminating the side effects related to off-target tissue activation of A1 AR. This review provides an overview of the medicinal chemistry and therapeutic potential of various agonists/partial agonists, antagonists and allosteric modulators of A1 AR, with a particular emphasis on their current status and future perspectives in clinical settings.

1 January 2019
Verified
Book Chapter
Closed access
PDPran Kishore Deb
Pran Kishore Deb
SKSarah Falah Kokaz
Sarah Falah Kokaz
SASARA Abed
SARA Abed
APAnant Paradkar
Anant Paradkar
RTRakesh K. Tekade
Rakesh K. Tekade

13 March 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Katharigatta VenugopalaKatharigatta Venugopala
Katharigatta Venugopala
PRPushpalatha Ramachandra
Pushpalatha Ramachandra
CTChristophe Tratrat
Christophe Tratrat
RGRaquel Gleiser
Raquel Gleiser
SBSubhrajyoti Bhandary
Subhrajyoti Bhandary
VMViresh Mohanlall
Viresh Mohanlall
Malaria, affecting all continents, remains one of the life-threatening diseases introduced by parasites that are transmitted to humans through the bites of infected Anopheles mosquitoes. Although insecticides are currently used to reduce malaria transmission, their safety concern for living systems, as well as the environment, is a growing problem. Therefore, the discovery of novel, less toxic, and environmentally safe molecules to effectively combat the control of these vectors is in high demand. In order to identify new potential larvicidal agents, a series of 2-aryl-1,2-dihydroquinazolin-4-one derivatives were synthesized and evaluated for their larvicidal activity against Anopheles arabiensis. The in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of the compounds were also investigated and most of the derivatives possessed a favorable ADMET profile. Computational modeling studies of the title compounds demonstrated a favorable binding interaction against the acetylcholinesterase enzyme molecular target. Thus, 2-aryl-1,2-dihydroquinazolin-4-ones were identified as a novel class of Anopheles arabiensis insecticides which can be used as lead molecules for the further development of more potent and safer larvicidal agents for treating malaria.

1 January 2019
Verified
Book Chapter
Closed access
SASARA Abed
SARA Abed
PDPran Kishore Deb
Pran Kishore Deb
HSHiba Salim Surchi
Hiba Salim Surchi
SKSarah Falah Kokaz
Sarah Falah Kokaz
SJSaadh Mohamed Jamal
Saadh Mohamed Jamal
RTRakesh K. Tekade
Rakesh K. Tekade

1 January 2018
Verified
Book Chapter
Closed access
AIArpna Indurkhya
Arpna Indurkhya
MPMahendra Patel
Mahendra Patel
PSPiyoosh Sharma
Piyoosh Sharma
SASARA Abed
SARA Abed
ASAbeer Jabra Shnoudeh
Abeer Jabra Shnoudeh
RTRakesh K. Tekade
Rakesh K. Tekade